6-[(E)-2-(1,3-benzodioxol-5-yl)ethenyl]-2-methyl-4,5-dihydropyridazin-3-one | 1038342-71-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 6-[(E)-2-(1,3-benzodioxol-5-yl)ethenyl]-2-methyl-4,5-dihydropyridazin-3-one
• CAS: 1038342-71-0
• 化学式: C₁₄H₁₄N₂O₃
• 分子量: 258.277
• InChiKey: BEHPWTPJYAIXCG-DUXPYHPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  51.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (E)-6-benzo[1,3]dioxol-5-yl-4-oxo-hex-5-enoic acid 、 甲基肼 在 溶剂黄146 作用下， 反应 4.0h， 以87%的产率得到6-[(E)-2-(1,3-benzodioxol-5-yl)ethenyl]-2-methyl-4,5-dihydropyridazin-3-one
  参考文献：
  名称：

  Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity

  摘要：

  Herein, we report the design, synthesis, and pharmacological properties of a series of arylethenylpyridazinones 3a-h and arylethylpyridazinone derivatives 3k-i from the corresponding aryloxohexenoic 1a-e and aryloxohexanoic acids 2a, d, respectively. The synthesized compounds were tested for their anti-inflammatory activity in carrageenan-induced rat paw edema model. Compound 3j demonstrated the greatest in vivo activity with ED50 equal to 17 mu mol compared with celecoxib with no ulceration on the gastric mucosa. Docking study of the synthesized compounds into the active site of COX-2 revealed a similar binding mode to RS-57067, a COX-2 inhibitor. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.04.007

文献信息

• Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity
  作者：Khaled Abouzid、Salma A. Bekhit

  DOI：10.1016/j.bmc.2008.04.007

  日期：2008.5

  Herein, we report the design, synthesis, and pharmacological properties of a series of arylethenylpyridazinones 3a-h and arylethylpyridazinone derivatives 3k-i from the corresponding aryloxohexenoic 1a-e and aryloxohexanoic acids 2a, d, respectively. The synthesized compounds were tested for their anti-inflammatory activity in carrageenan-induced rat paw edema model. Compound 3j demonstrated the greatest in vivo activity with ED50 equal to 17 mu mol compared with celecoxib with no ulceration on the gastric mucosa. Docking study of the synthesized compounds into the active site of COX-2 revealed a similar binding mode to RS-57067, a COX-2 inhibitor. (C) 2008 Elsevier Ltd. All rights reserved.